Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam · Delayed Price · Currency is VND 18,400
0.00 (0.00%)
At close: May 13, 2026
HNX:MED Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 15,833 | 15,247 | 11,744 | 6,366 | 3,747 |
Depreciation & Amortization | 7,169 | 7,916 | 8,444 | 10,020 | 9,536 |
Other Amortization | 7.43 | - | - | - | - |
Loss (Gain) From Sale of Assets | - | -773.89 | -6,395 | -3,782 | -3,902 |
Other Operating Activities | 1,572 | 2,015 | -1,936 | 1,683 | -2,016 |
Change in Accounts Receivable | 27,760 | 23,261 | 37,508 | 2,063 | 58,829 |
Change in Inventory | -5,670 | 15,425 | -1,583 | -14,664 | 4,843 |
Change in Accounts Payable | -51,176 | -16,803 | -95,351 | 26,049 | -6,766 |
Change in Other Net Operating Assets | -873.16 | 1,368 | 3,660 | -1,503 | -2,160 |
Operating Cash Flow | -5,377 | 47,653 | -43,908 | 26,231 | 62,110 |
Operating Cash Flow Growth | - | - | - | -57.77% | -30.49% |
Capital Expenditures | -9,767 | -9,979 | -40,594 | -117,270 | -54,364 |
Sale of Property, Plant & Equipment | - | - | 43.64 | 240.21 | 992.27 |
Investment in Securities | 5,300 | 8,000 | 72,400 | -44,000 | 6,000 |
Other Investing Activities | 510.86 | 1,121 | 7,204 | 3,354 | 3,479 |
Investing Cash Flow | -3,956 | -858.42 | 39,054 | -157,676 | -43,893 |
Short-Term Debt Issued | 133,282 | 157,753 | 193,594 | 205,142 | 180,305 |
Total Debt Issued | 133,282 | 157,753 | 193,594 | 205,142 | 180,305 |
Short-Term Debt Repaid | -127,155 | -194,430 | -219,966 | -182,973 | -192,316 |
Total Debt Repaid | -127,155 | -194,430 | -219,966 | -182,973 | -192,316 |
Net Debt Issued (Repaid) | 6,127 | -36,676 | -26,372 | 22,168 | -12,012 |
Issuance of Common Stock | - | - | - | 153,104 | - |
Common Dividends Paid | -14,997 | -11,021 | -6,426 | -8,816 | -13,281 |
Financing Cash Flow | -8,870 | -47,697 | -32,799 | 166,456 | -25,293 |
Foreign Exchange Rate Adjustments | -7.45 | -19.53 | 2.9 | -28.96 | - |
Net Cash Flow | -18,210 | -922.47 | -37,650 | 34,983 | -7,076 |
Free Cash Flow | -15,144 | 37,674 | -84,502 | -91,039 | 7,746 |
Free Cash Flow Growth | - | - | - | - | -87.20% |
Free Cash Flow Margin | -4.13% | 8.50% | -20.98% | -22.70% | 2.25% |
Free Cash Flow Per Share | -1220.28 | 3035.74 | -6809.19 | -9696.32 | 1234.13 |
Cash Interest Paid | 2,311 | 3,816 | 5,432 | 4,953 | 3,643 |
Cash Income Tax Paid | 3,399 | 3,874 | 4,719 | 272.58 | 2,383 |
Levered Free Cash Flow | -18,427 | 29,827 | -101,170 | -115,881 | 14,442 |
Unlevered Free Cash Flow | -16,980 | 32,195 | -97,798 | -112,754 | 16,703 |
Change in Working Capital | -29,959 | 23,250 | -55,765 | 11,945 | 54,746 |